{
    "nct_id": "NCT06075810",
    "official_title": "A Phase 1 Open-Label, First-in-Human Trial of Oral MBQ-167 as Single Agent in Participants With Advanced Breast Cancer",
    "inclusion_criteria": "* The investigator will evaluate these and other criteria to determine whether a participant can be included in this study.\n* Histologically and/or cytologically confirmed advanced breast cancer which has progressed after treatment with approved therapies or for which there are no standard therapies available.\n* Participants with known brain metastases may be eligible if specific conditions are met.\n* Life expectancy â‰¥6 months, in the opinion of the investigator, after starting MBQ-167.\n* Are able to swallow capsules twice daily with a meal.\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 21 Years",
    "exclusion_criteria": "* The investigator will evaluate these and other criteria to determine whether a participant should be excluded from this study.\n* Inability to take oral medication, or malabsorption syndrome or any other uncontrolled gastrointestinal condition (e.g., nausea, diarrhea, or vomiting) that might impair the bioavailability of MBQ-167.\n* Females who are pregnant or breastfeeding.\n* Participants who have received any anticancer treatment within 4 weeks or any investigational agent within 28 days prior to the first dose of trial drug or who have not recovered from any acute toxicity greater than Grade 0 or 1 related to previous anticancer treatment.\n* Participants who have received any anticancer treatment within 4 weeks or any investigational agent within 28 days prior to the first dose of trial drug or who have not recovered from any acute toxicity greater than Grade 0 or 1 related to previous anticancer treatment.\n* Active malignancies other than advanced breast cancer will be excluded from the study.",
    "miscellaneous_criteria": "Key"
}